Vimarsana
Biggest News Aggregation in the World

Page 44 - Use Authorization News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Use Authorization. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Use Authorization Today - Breaking & Trending Today

CDC panel OKs recommending Pfizer COVID-19 booster for kids 5 to 11 - Vimarsana News

CDC panel OKs recommending Pfizer COVID-19 booster for kids 5 to 11

U.S. health advisers are urging a booster dose of Pfizer's COVID-19 vaccine for kids ages 5 to 11.

FDA Approves Lilly and Incyte's Olumiant For Hospitalized COVID-19 Patients - Vimarsana News

FDA Approves Lilly and Incyte's Olumiant For Hospitalized COVID-19 Patients

The U.S. Food and Drug Administration (FDA) has given approval for the commercialization of Eli Lilly and Company and Incyte’s Olumiant (baricitinib), setting a precedent for COVID-19 treatments.

Novavax Missed Q1 Estimates By a Mile: Should Investors Worry? - Vimarsana News

Novavax Missed Q1 Estimates By a Mile: Should Investors Worry?

The vaccine maker faces a few big uncertainties.

Source: fool.com
CytoSorbents Reports First Quarter 2022 Results and Revises 2022 Outlook - Vimarsana News

CytoSorbents Reports First Quarter 2022 Results and Revises 2022 Outlook

Press release content from PR Newswire. The AP news staff was not involved in its creation.

Source: apnews.com
CytoSorbents Reports First Quarter 2022 Results and Revises 2022 Outlook - Vimarsana News

CytoSorbents Reports First Quarter 2022 Results and Revises 2022 Outlook

Q1 2022 total revenue was $8.7 million, including product sales of $7.9 million.  Core non-COVID-19 product sales were an estimated $7.6 million, ...